Experimental Study of the Antitumor Activity of Polymetalacrylates against Animal Transplantable Tumors

Larisa A. Ostrovskaya, M. G. Voronkov, D. B. Korman, M. M. Fomina, N. V. Bluhterova, V. A. Rikova, K. A. Abzaeva, L. V. Zhilitskaya

A.E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia.
N.M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Russian, Moscow.

DOI: 10.4236/jct.2010.12010                

Abstract

The antitumor activity of the fourteen polymetalacrylates against two models of murine solid tumors (Lewis lung carcinoma and Acatol adenocarcinoma) as well as the acute toxicity of these compounds has been studied. It was shown that polyacrylates of noble metals (argent, aurum, platinum), namely argacryl (М = Ag), auracryl (М = Au) and platacryl (М = Pt) were the most effective agents among tested compounds against studied tumors. Thus, the tumor growth inhibitory effect of argacryl against Lewis lung carcinoma was equal to 90%, the life-span of treated by this compound animals has increased on 50% in comparison with control. Auracryl induced the inhibition of the Lewis lung carcinoma and Acatol adenocarcinoma development on 60 and 65%, correspondingly and the increasing of the mean life-span of animals with Lewis lung carcinoma on 20% in comparison with control. Platacryl inhibited the growth of Lewis lung carcinoma on 40% increasing the mean life-span of animals on 25% in comparison with control. In this way it was established that argacryl is the agent with the strongest antitumor activity among studied polymetalacrylates. On the basis of obtained data it seems possible to consider polymetalacrylates as a group of agents with the potential antitumor activity suitable for the further deep experimental investigation.

Keywords

Polymetalcrylates, Antitumor Activity, Transplantable Tumors of Animals

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	D. B. Korman, “Foundations of the Anticancer Chemothe-rapy,” Practical Medicine, Мoscow, 2006, p. 503.
[2]	M. G. Voronkov, A. S. Kogan, L. M. Antonik, et al., “Antimicrobial and Hemostatic Actions of Silver Deriva-tives of Polyacrylic Acid,” Chemical Pharmaceutical Journal, Vol. 35, No. 9, 2001, рp. 19-20.
[3]	M. G. Voronkov, L. M. Antonik, K. A. Abzaeva, et al., “Antibacterial and Hemostatic Properties of Silver Deriv-atives of Polyacrylic Acid,” Chemical Pharmaceutical Journal, Vol. 36, No. 2, 2002, рp. 27-29.
[4]	М. G. Voronkov, K. А. Abzaeva, L. V. Zhilitskaya and L. А. Оstrovskaya, et al., “Antitumor Agent Referring to the Group of Metalorganic Derivatives of Polyacrylic Acid”, Patent of the RF, Bulletin of Inventions, No. 31, 2009.
[5]	K. A. Abzaeva, M. G. Voronkov, L. V. Zhilitskaya, et al., “Incomplete Zinc Salt of Polyacrylic Acid, its Synthesis and its Antiseptic, Hemostatic and Wound Healing Actions at External Administration,” Patent of the RF, Bulletin of Inventions, No. 2, 2008.
[6]	K. A. Abzaeva, M. G. Voronkov and L. V. Zhilitskaya, “Pharmacological Activity of Ziacryl, a Zinc Salt of Po-lyacrylic Acid,” Chemical Pharmaceutical Journal, Vol. 43, No. 12, 2009, pp. 68-71.
[7]	K. A. Abzaeva, M. G. Voronkov and L. V. Zhilitskaya, “Pharmacological Properties of Poly (Zincacrylate) Zia-cryl,” Doklady Biological Sciences (Biological Sciences Reports), Vol. 424. No. 1, 2009, pp. 135- 137.
[8]	N. O. Jarosh, K. A. Abzaeva and L. V. Zhilitskaya, “Pharmacological Properties of Metal Derivatives of Po-lyacrylic Acid,” Bulletin of East-Siberian Research Centre, Irkutsk, Vol. 60, No. 2, 2008, pp. 120.
[9]	E. V. Аnufrieva, R. А. Gromova, V. В. Luschik, et al., “Influence of Aluminium Salts on Structure Formation in Polymer Solutions,” Polymer Science, Series B, Vol. 38, No. 9, 1996, pp. 1614-1616.
[10]	K. A. Abzaeva, M. G. Voronkov and V. A. Lopyrev, Po-lymer Science, Series B, Vol. 39, No. 11-12, 1997, pp. 409-428.
[11]	М. G. Voronkov, et al., “Synthetic Method for Salt of Polyacrylic Acid,” Bulletin of Inventions, No. 46, 1979, p. 223.
[12]	U. F. Krilov, “Register of medicines of Russia,” In-pharmchim (Inpharmchemistry), Моscow, 1993, p. 1006.
[13]	М. G. Voronkov, et al., “Device for the Synthesis of Iron Containing Polyacrylic Acid,” Patent of the RF, Bulletin of Inventions, No. 16, 1998.
[14]	М. G. Voronkov, V. А. Lopiriov and L. М. Аntonic, et al., “Argacryl as a New Antiseptic and Hemostatic Prepara-tion,” Patent of the RF, Bulletin of Inventions, No. 1, 2004, p. 781.
[15]	A. M. Bhagwat, S. Save, S. Burli and S. G. Karki, Indian Journal of Pathology and Microbiology, Vol. 44, No. 4, 2001, pp. 431-433.
[16]	М. D. Маshkovskii, “Medicines. Manual for Doctors”, The New Wave, Моscow, Vol. 2, 2003, p. 608.
[17]	“The Application of the Silver Drugs in Medicine,” In: Е. М. Blagitko Ed., ZАО “Vector-Best”, Novosibirsk, 2003, p. 115.
[18]	I. А. Еfimenko, “Bio-coordination Chemistry of Platinum Metals－The Base for the Design and Development of Drugs,” Coordination Chemistry, Vol. 24, No. 4, 1998, p. 282.
[19]	M. Gielen and E. R. T. Tiekink, “Metallotherapeutic Drugs and Metal-Based Diagnostic Agents,” John Wiley and Sons, Ltd., Chichester, 2005, p. 598.
[20]	R. P. Evstigneev and V. P. Pchelkin, “Catalytic and Bio-logical Activity of Organic Complexes of Noble Metals,” Chemical Pharmaceutical Journal, Vol. 37, No. 11, 2003, pp. 9-13.
[21]	Е. М. Тreschalina, О. S. Jukova, G. K. Gerasimova, et al., “Guide of the Experimental (Preclinical) Study of Phar-macological Compounds,” In: R. U. Habriev Ed., Мedicine, Мoscow, 2005, pp. 637-651.
[22]	N. T. J. Bailey, “Statistical Methods in Biology,” Publish-ing House of Foreign Literature, Моscow, 1962, p. 251.